Logo

NCI Purchases Illumina BeadLab for Cancer Genotyping Studies

Sep 01, 2005

NEW YORK, Sept. 1 (GenomeWeb News) - The National Cancer Institute has purchased genotyping instrumentation from Illumina for its Advanced Technology Center core genotyping facility in Gaithersburg, Md., the company said today.

 

The facility plans to use the BeadLab station initially for research into the genetics of breast and prostate cancer and will support the NCI's Cancer Genetic Markers of Susceptibility initiative.

 

NCI researchers plan to genotype approximately 15,000 loci for each of more than 6,000 DNA samples. Later, they want to develop a pool of 1,536 SNP assays associated with prostate cancer and genotype over 15,000 samples to validate a set of biomarkers for prostate cancer.

 

Illumina has already been providing genotyping services for the NCI's SNP500 cancer project.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.